Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

1.880 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,300
Open 1.880
Bid (Size) 1.870 (3)
Ask (Size) 1.890 (9)
Prev. Close 1.880
Today's Range 1.880 - 1.880
52wk Range 1.639 - 12.51
Shares Outstanding 305,252,194
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BFA Law Notifies Iovance Biotherapeutics, Inc. (IOVA) Investors that the Company was Sued for Fraud - Contact the Firm by July 14 if You Lost Money
Via ACCESS Newswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire

Performance

YTD
-75.9%
-75.9%
1 Month
+8.7%
+8.7%
3 Month
-46.0%
-46.0%
6 Month
-74.9%
-74.9%
1 Year
-77.0%
-77.0%

More News

Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
Via ACCESS Newswire
Iovance Biotherapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - IOVA
Via NewMediaWire
Topics Fraud Lawsuit
Iovance Biotherapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - IOVA
Via TheNewswire.com
Topics Fraud Lawsuit
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Krispy Kreme, Strategy Incorporated, Organon, and Iovance and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA
From The Rosen Law Firm PA
Via GlobeNewswire
Deadline Approaching for Investors of Iovance Biotherapeutics, Inc. (IOVA) - Contact Kaplan Fox Before July 14, 2025
Via NewMediaWire
Topics Lawsuit
Deadline Approaching for Investors of Iovance Biotherapeutics, Inc. (IOVA) - Contact Kaplan Fox Before July 14, 2025
Via TheNewswire.com
Topics Lawsuit
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA
From Pomerantz LLP
Via GlobeNewswire
IOVA FRAUD NOTIFICATION: Did Iovance Biotherapeutics, Inc. Commit Securities Fraud? Investors Are Urged to Contact BFA Law by July 14 to Potentially Recover Losses
Via ACCESS Newswire
IOVA COURT NEWS: Iovance Biotherapeutics, Inc. Was Sued for Securities Fraud - Investors Are Urged to Contact BFA Law By July 14 Legal Deadline
Via ACCESS Newswire
Iovance’s (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure - Hagens Berman
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
Via ACCESS Newswire
IOVA COURT NOTICE: Lose Money on Iovance Biotherapeutics, Inc.? Contact BFA Law before Upcoming Class Action Deadline
Via ACCESS Newswire
Kaplan Fox Alerts Investors to a Deadline for a Securities Fraud Class Action Lawsuit Against Iovance Biotherapeutics, Inc. (IOVA) - Contact Kaplan Fox Before July 14, 2025
Via NewMediaWire
Topics Fraud Lawsuit
Kaplan Fox Alerts Investors to a Deadline for a Securities Fraud Class Action Lawsuit Against Iovance Biotherapeutics, Inc. (IOVA) - Contact Kaplan Fox Before July 14, 2025
Via TheNewswire.com
Topics Fraud Lawsuit
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA
From Pomerantz LLP
Via GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVA
From Kahn Swick & Foti, LLC
Via GlobeNewswire
Iovance’s (IOVA) CFO Resigns Amid Launch Setbacks And Legal Pressure - Hagens Berman
Via ACCESS Newswire
IOVA NOTIFICATION: Iovance Biotherapeutics, Inc. Shareholders are Notified of The Ongoing Securities Fraud Class Action Lawsuit - Contact BFA Law by July 14
Via ACCESS Newswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Krispy Kreme, Strategy Incorporated, Organon, and Iovance and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
IOVA SHAREHOLDER ALERT: BFA Law Reminds Iovance Biotherapeutics, Inc. Investors of Upcoming July 14 Class Action Deadline - Contact the Firm if You Suffered Losses
Via ACCESS Newswire

Frequently Asked Questions

Is Iovance Biotherapeutics, Inc. - Common Stock publicly traded?
Yes, Iovance Biotherapeutics, Inc. - Common Stock is publicly traded.
What exchange does Iovance Biotherapeutics, Inc. - Common Stock trade on?
Iovance Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock?
The ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock is IOVA on the Nasdaq Stock Market
What is the current price of Iovance Biotherapeutics, Inc. - Common Stock?
The current price of Iovance Biotherapeutics, Inc. - Common Stock is 1.880
When was Iovance Biotherapeutics, Inc. - Common Stock last traded?
The last trade of Iovance Biotherapeutics, Inc. - Common Stock was at 06/24/25 04:00 PM ET
What is the market capitalization of Iovance Biotherapeutics, Inc. - Common Stock?
The market capitalization of Iovance Biotherapeutics, Inc. - Common Stock is 573.87M
How many shares of Iovance Biotherapeutics, Inc. - Common Stock are outstanding?
Iovance Biotherapeutics, Inc. - Common Stock has 574M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.